Akari Therapeutics plc ADR (0.01 USD) vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| AKTX | JNJ | |
|---|---|---|
| Market Cap | $17.83 million | $650.65 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | $-30,960,000 | $21.04 billion |
JNJ leads on 2 of 2 size & scale factors.
Valuation
| AKTX | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.32 |
| Price / Book | 0.96 | 7.66 |
| Price / Sales | — | 6.64 |
AKTX leads on 1 of 1 valuation factors.
Profitability
| AKTX | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | -166.50% | 24.76% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| AKTX | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.99% |
| Payout Ratio | — | 62.18 |
AKTX and JNJ split the dividend factors evenly.
Risk & Sentiment
| AKTX | JNJ | |
|---|---|---|
| Short Interest | 30.21% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: AKTX overview, AKTX financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.